EGFR-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with “Stop-And-Go” Osimertinib

A 69-year-old man with post-operative recurrence of lung adenocarcinoma was treated with multiple chemotherapies, including epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. A second biopsy revealed an EGFR T790M mutation. As 10th-line chemotherapy, osimertinib was initiated. After...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Keigo, Naoki, Katsuhiko, Kuroda, Aoi, Yasuda, Hiroyuki, Kawada, Ichiro, Soejima, Kenzo, Betsuyaku, Tomoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919862/
https://www.ncbi.nlm.nih.gov/pubmed/29269665
http://dx.doi.org/10.2169/internalmedicine.9609-17
_version_ 1783317713623449600
author Kobayashi, Keigo
Naoki, Katsuhiko
Kuroda, Aoi
Yasuda, Hiroyuki
Kawada, Ichiro
Soejima, Kenzo
Betsuyaku, Tomoko
author_facet Kobayashi, Keigo
Naoki, Katsuhiko
Kuroda, Aoi
Yasuda, Hiroyuki
Kawada, Ichiro
Soejima, Kenzo
Betsuyaku, Tomoko
author_sort Kobayashi, Keigo
collection PubMed
description A 69-year-old man with post-operative recurrence of lung adenocarcinoma was treated with multiple chemotherapies, including epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. A second biopsy revealed an EGFR T790M mutation. As 10th-line chemotherapy, osimertinib was initiated. After 24 weeks, chest computed tomography (CT) revealed asymptomatic ground-glass opacities in both lobes. After four weeks of osimertinib discontinuation, imaging revealed rapid lung cancer progression. Osimertinib was resumed. After 11 weeks, CT revealed decreased lung nodules with no exacerbation of interstitial lung disease. We describe a patient who experienced transient asymptomatic pulmonary opacities during treatment with osimertinib, which was successfully managed by a “stop-and-go” approach.
format Online
Article
Text
id pubmed-5919862
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-59198622018-04-27 EGFR-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with “Stop-And-Go” Osimertinib Kobayashi, Keigo Naoki, Katsuhiko Kuroda, Aoi Yasuda, Hiroyuki Kawada, Ichiro Soejima, Kenzo Betsuyaku, Tomoko Intern Med Case Report A 69-year-old man with post-operative recurrence of lung adenocarcinoma was treated with multiple chemotherapies, including epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. A second biopsy revealed an EGFR T790M mutation. As 10th-line chemotherapy, osimertinib was initiated. After 24 weeks, chest computed tomography (CT) revealed asymptomatic ground-glass opacities in both lobes. After four weeks of osimertinib discontinuation, imaging revealed rapid lung cancer progression. Osimertinib was resumed. After 11 weeks, CT revealed decreased lung nodules with no exacerbation of interstitial lung disease. We describe a patient who experienced transient asymptomatic pulmonary opacities during treatment with osimertinib, which was successfully managed by a “stop-and-go” approach. The Japanese Society of Internal Medicine 2017-12-21 2018-04-01 /pmc/articles/PMC5919862/ /pubmed/29269665 http://dx.doi.org/10.2169/internalmedicine.9609-17 Text en Copyright © 2018 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Kobayashi, Keigo
Naoki, Katsuhiko
Kuroda, Aoi
Yasuda, Hiroyuki
Kawada, Ichiro
Soejima, Kenzo
Betsuyaku, Tomoko
EGFR-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with “Stop-And-Go” Osimertinib
title EGFR-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with “Stop-And-Go” Osimertinib
title_full EGFR-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with “Stop-And-Go” Osimertinib
title_fullStr EGFR-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with “Stop-And-Go” Osimertinib
title_full_unstemmed EGFR-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with “Stop-And-Go” Osimertinib
title_short EGFR-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with “Stop-And-Go” Osimertinib
title_sort egfr-mutant non-small cell lung cancer accompanied by transient asymptomatic pulmonary opacities successfully treated with “stop-and-go” osimertinib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919862/
https://www.ncbi.nlm.nih.gov/pubmed/29269665
http://dx.doi.org/10.2169/internalmedicine.9609-17
work_keys_str_mv AT kobayashikeigo egfrmutantnonsmallcelllungcanceraccompaniedbytransientasymptomaticpulmonaryopacitiessuccessfullytreatedwithstopandgoosimertinib
AT naokikatsuhiko egfrmutantnonsmallcelllungcanceraccompaniedbytransientasymptomaticpulmonaryopacitiessuccessfullytreatedwithstopandgoosimertinib
AT kurodaaoi egfrmutantnonsmallcelllungcanceraccompaniedbytransientasymptomaticpulmonaryopacitiessuccessfullytreatedwithstopandgoosimertinib
AT yasudahiroyuki egfrmutantnonsmallcelllungcanceraccompaniedbytransientasymptomaticpulmonaryopacitiessuccessfullytreatedwithstopandgoosimertinib
AT kawadaichiro egfrmutantnonsmallcelllungcanceraccompaniedbytransientasymptomaticpulmonaryopacitiessuccessfullytreatedwithstopandgoosimertinib
AT soejimakenzo egfrmutantnonsmallcelllungcanceraccompaniedbytransientasymptomaticpulmonaryopacitiessuccessfullytreatedwithstopandgoosimertinib
AT betsuyakutomoko egfrmutantnonsmallcelllungcanceraccompaniedbytransientasymptomaticpulmonaryopacitiessuccessfullytreatedwithstopandgoosimertinib

Ejemplares similares